Publications

Publications

At Bayer, we are working in collaboration with the leading scientific, academic, and community partners to improve our understanding of cardiorenal diseases.  

 

We invite you to explore Bayer-supported publications pertaining to chronic kidney disease associated with type 2 diabetes. This library is not intended to serve as a comprehensive repository of all publications. Publications not supported by Bayer are not included. Access to the full text of publications may depend on journal access rights.

 

To help narrow down your search, choose the relevant tags and click apply. Applying multiple tags will narrow your results.

 

Last updated “April 30, 2024”.

Types of Enhancements Available

audio
Audio
infographic
Graphical Abstract
PLS
Plain Language Summary
video
Video
other
Others

To help narrow down your search, select the relevant filters from the dropdowns and Click Apply

Hold down Ctrl key on keyboard to select multiple years

Total available publications: 205    

Filtered results: 205

Cardiovascular-kidney-metabolic effects: Steroidal and nonsteroidal mineralocorticoid receptor antagonists

Bozkurt B et al., Rev. Cardiovasc. Med. 2025;26(7):38690.

Bozkurt B, Januzzi JL, Bansal S,, 29 07 2025

A primary care guide to the screening and pharmacologic management of chronic kidney disease in people living with type 2 diabetes

Wright EE et al., Primary care diabetes. 2025.

Eugene EE, Cebrian A, Ngui D, 10 07 2025

A primary care guide to the screening and pharmacologic management of chronic kidney disease in people living with type 2 diabetes

Wright EE et al., Clin diabetes.2025;cd250013.

Eugene EE., Cebrian A, Ngui D, 10 07 2025

Efficacy and safety of finerenone in patients with an acute change in estimated glomerular filtration rate in the prespecified FIDELITY pool analysis

Navaneethan SD et al. Kidney International. 2025;108(1):136-144.

Navaneethan SD, Anker SD, Filippatos G, 01 07 2025

Finerenone and clinical outcomes in CKD and type 2 diabetes by frailty index: FIDELITY post hoc analysis

Rossing P et al. CJASN. 2025;20(7):968-977.

Rossing P, Birkenfeld AL, Fioretto P, 01 07 2025

Interconnected pathways and emerging therapies in chronic kidney disease and heart failure: A comprehensive review

Bauersachs J et al., ESC Heart Failure. 2025.

Bauersachs J, Kato ET, Rangaswami J., 18 06 2025

Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes

Agarwal R, et al. New England Journal of Medicine. 2025.

Agarwal, R., Green, J.B., Heerspink, H.J., et al., 05 06 2025

The role of finerenone in the concomitant management of chronic kidney disease-type 2 diabetes and the implication for heart failure prevention and treatment

Taub PR, et al. Heart Failure Reviews. 2025;1-4.

Taub PR, Greene SJ, Fudim M, 31 05 2025

Albuminuria as a diagnostic criterion and a therapeutic target in heart failure and other cardiovascular disease

Bozkurt B, et al. European Journal of Heart Failure. 2025.

Bozkurt B, Rossignol P, Vassalotti JA, 27 05 2025

Finerenone effects on biomarkers: an analysis from the FIGARO-DKD trial

Berger M, et al. European Heart Journal. 2025;ehaf316.

Berger M, MacNamara A, Ferreira JP, et al., 26 05 2025